Building Successful Startups in Industrial Biotechnology

October
,
2019

Industrial biotech startups are typically founded by technical individuals — engineers and scientists with little experience in the world of business. This article describes ways to avoid some of the pitfalls that budding startups face.

Starting a company in the industrial biotechnology field requires an entrepreneur to develop varied skills that contribute to its success, such as communication and negotiating skills. Although success is not entirely defined, we often consider a successful startup as one that creates an innovative product, demonstrates its economic viability, and then either sells the product and becomes profitable, or partners with a large company to jointly commercialize the product. At some point in time, this process leads to a so-called liquidity event for the company’s shareholders, such as a public listing or acquisition of the startup by another company for cash or shares.

Sofinnova Partners has been helping entrepreneurs build startups for more than 45 years and has invested in more than 550 companies over that period. The goal of our industrial biotech practice is to develop new products that can address multiple societal challenges. Fundamentally, we believe that biology can provide the world with an unprecedented ability to develop more sustainable, better, faster, and cheaper solutions to pressing problems in the agriculture, food, materials, chemicals, and energy sectors.

When we started our efforts in industrial biotech a few years ago (after focusing the entire firm on life sciences), we leveraged our experience in building pharmaceutical biotech companies and expertise in working with early-stage entrepreneurs. Currently, we have 15 investments in the industrial biotech sector. Our objective is to tap into a new and growing market to leverage mature biotechnology tools and apply them in an industrial context.

The key advantage of an investment firm (over an entrepreneur) is that it often invests in a portfolio of companies, allowing it to have a helicopter view of the sector and rapidly apply knowledge and learnings it gains from one company to its dealings with others. Whenever possible, Sofinnova Partners attempts to generalize some of these teachings and develop a working set of guidelines for us and for our companies. This article shares some of the lessons that we have learned and describes some of the common challenges that young startups face. The article also describes how startups can communicate value and develop partnerships, as well as raise capital and generate liquidity for investors...

Author Bios: 

Joško Bobanović

Joško Bobanović joined Sofinnova Partners in 2010 as Partner dedicated to activities in industrial biotech. He focuses on early stage deals in Europe and North America with applications in chemicals, agriculture, food, feed and synthetic biology. Joško sits on the boards of Metgen, Synthace, Cellucomp, Comet Bio, DNA Script and Biosyntia. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital in Montreal, Canada. Prior to his venture capital career he created an internet startup and a software company. After completing his PhD studies Joško developed real-...Read more

Would you like to access the complete CEP Article?

No problem. You just have to complete the following steps.

You have completed 0 of 2 steps.

  1. Log in

    You must be logged in to view this content. Log in now.

  2. AIChE Membership

    You must be an AIChE member to view this article. Join now.

Copyright Permissions: 

Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.